Narsoplimab Biosimilar – Anti-MASP2 mAb – Research Grade

Narsoplimab Biosimilar – Anti-MASP2 mAb

About Narsoplimab biosimilar

Narsoplimab is a human monoclonal antibody. This biosimilar belong to the family of immunoglobulin G4- type. It is targeting mannan-binding lectin-associated serine protease-2 (MASP-2). This enzyme is the effector of the lectin pathway of the complement system. Narsoplimab is designed to prevent complement-mediated inflammation, but also endothelial damage, whitout interactions with other pathways of innate immunity. Indeed, Narsoplimab is developed to be a treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

Narsoplimab’s action

The lectin pathway is first activated by tissue damage and microbial infection. It is one of the principal pathways of complement system. Fortunately, inhibition of MASP-2 seems not to interfere with the classical complement pathway, which could be critical in the acquired immune response to infection.
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a complication of stem cell transplantation, which is often lethal. HSCT-TMA is a multifactorial disorder which is caused by endothelial cell damage. These could be induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and every factor associated with stem cell transplantation.

A research grade biosimilar

Narsoplimab biosimilar is a human antibody produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.